GPX3 represses pancreatic cancer cell proliferation, migration and invasion, and improves their chemo‑sensitivity by...

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Pancreatic cancer (PC) is an aggressive malignancy with a poor prognosis.
• Glutathione peroxidase 3 (GPX3) has been implicated in the pathogenesis of various cancers.
• The specific role and mechanism of GPX3 in PC remain largely unexplored.

Purpose of the Study:

• To investigate the regulatory function of GPX3 in pancreatic cancer.
• To elucidate the underlying molecular mechanisms by which GPX3 influences PC progression.
• To assess GPX3's potential as a therapeutic target and prognostic biomarker in PC.

Main Methods:

• Bioinformatics analysis to predict GPX3 expression and prognostic correlation.
• Quantitative PCR and Western blot to measure GPX3 levels in PC cells.
• In vitro assays (proliferation, migration, invasion, apoptosis) following GPX3 overexpression.
• Western blot analysis of EMT, apoptosis, and JNK signaling pathways.
• Rescue experiments using anisomycin to activate JNK signaling.

Main Results:

• GPX3 was found to be downregulated in PC tissues and associated with a favorable prognosis.
• GPX3 overexpression significantly inhibited PC cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT).
• GPX3 enhanced the sensitivity of PC cells, including gemcitabine-resistant cells, to gemcitabine (GEM).
• GPX3 suppressed JNK/c-Jun signaling, and this effect was reversed by anisomycin, which also restored malignant phenotypes and chemo-resistance.

Conclusions:

• GPX3 functions as a tumor suppressor in pancreatic cancer.
• GPX3 inhibits PC progression and chemo-resistance by suppressing the JNK/c-Jun signaling pathway.
• GPX3 represents a promising therapeutic target for pancreatic cancer treatment.